{"id":"NCT00624286","sponsor":"Novartis","briefTitle":"Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Indacaterol (150 μg o.d.) in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2008-02-27","resultsPosted":"2011-08-18","lastUpdate":"2011-08-18"},"enrollment":416,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Indacaterol 150 μg","otherNames":[]},{"type":"DRUG","name":"Placebo to indacaterol","otherNames":[]}],"arms":[{"label":"Indacaterol 150 μg","type":"EXPERIMENTAL"},{"label":"Placebo to indacaterol","type":"PLACEBO_COMPARATOR"}],"summary":"This study was designed to provide 12 weeks efficacy and safety data of the 150 μg once-daily (od) dose of indacaterol in chronic obstructive pulmonary disease (COPD).","primaryOutcome":{"measure":"Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day, Day 85)","timeFrame":"24 hours post-dose at the end of the study (Week 12 + 1 day, Day 85)","effectByArm":[{"arm":"Indacaterol 150 μg","deltaMin":1.48,"sd":0.018},{"arm":"Placebo to Indacaterol","deltaMin":1.35,"sd":0.019}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":120,"countries":["United States","Belgium","New Zealand"]},"refs":{"pmids":["22206353","22003288","20211002"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":211},"commonTop":["Chronic obstructive pulmonary disease","Cough"]}}